Serina Therapeutics Announces Appointment of Brendan P. Rae, Ph.D., J.D. as Chief Business Officer

Huntsville, AL, May 16th, 2016

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development based upon polyoxazoline (POZ™), announced today that the company has appointed Brendan P. Rae, Ph.D., J.D. as Chief Business Officer.

“We are very pleased to announce that Dr. Brendan P. Rae has joined us as Chief Business Officer. Brendan has over 20 years of expertise in licensing and commercial drug development for both early and late stage assets. Brendan has been directly involved in both small molecule and protein drug development programs across a wide range of therapeutic areas during his esteemed career. His expertise and breadth of knowledge will be essential to our success now as we move our first drug candidate further through clinical development, nominate additional compounds for IND-enabling studies, and execute additional partnerships with our platform”, said Randall Moreadith, MD, PhD, President and CEO at Serina Therapeutics.

"I am delighted to be joining the team at Serina Therapeutics at this exciting juncture in the company’s development,” said Dr. Rae. “The data from SER-214 will demonstrate the utility of Serina’s proprietary technology platform to improve the treatment options for patients suffering from Parkinson’s Disease. I look forward to working with the company’s present and future partners to further realize the transformative power of the technology in a broad range of therapeutic areas to make meaningful changes in the lives of patients and their families.”

SER-214 is Serina’s most advanced polymer conjugate, and is in Phase I now for patients with Parkinson’s disease. It is a once-per-week injectable that can be delivered in a standard insulin syringe. The conjugate is designed to deliver rotigotine continuously, thus providing continuous dopaminergic tone. This is a clinical strategy aimed at preventing the phasic peak and trough of many oral dopamine-like drugs that can lead to “wearing off” and dyskinesia. Such a strategy should obviate the disabling consequences of oral treatment with short-acting L-DOPA formulations and some dopamine agonists.

Serina’s pipeline programs are aimed primarily at oncology indications that address significant unmet medical needs. Polymers of POZ can be targeted to specific receptors on the surface of cancer cells using either small molecules or antibodies, and this approach may provide a much wider therapeutic index when employing very potent toxins attached to the polymer. These programs were validated in proof-of-concept in cell lines in 2015, and will be evaluated in confirmatory animal studies in 2016. Serina Therapeutics has partnered its technology platform with two of the top ten pharmaceutical companies in the world and is actively seeking additional partnerships.
About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. We believe our POZ technology provides strong differential characteristics that may demonstrate improved clinical benefits versus PEG and other polymer-based technologies. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit www.serinatherapeutics.com.